GO:0005150 interleukin-1, type I receptor binding: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0005150 (interleukin-1, type I receptor binding) is a molecular function describing the selective binding of a ligand to the Type I interleukin-1 receptor (IL-1R1).
• The principal physiological ligands are IL-1β and IL-1α, which bind IL-1R1 with high affinity and trigger pro-inflammatory signaling.
• The interaction is structurally well defined: the crystal structure of the IL-1R1–IL-1β complex revealed the receptor-ligand interface.
• Soluble decoy receptors and natural antagonists, such as IL-1Ra and IL-1R2, compete for the same binding site and modulate the pathway.
• Dysregulated IL-1/IL-1R1 binding is implicated in atherosclerosis, kidney disease, and other inflammatory conditions.
• CRISPR-based knockout, knock-in, and overexpression models enable causal testing of genes involved in this binding event.
Description
Interleukin-1 (IL-1) is a master cytokine of innate immunity, and its biological effects begin with binding to the Type I interleukin-1 receptor (IL-1R1). The Gene Ontology term GO:0005150, interleukin-1, type I receptor binding, captures this molecular function: the selective, high-affinity interaction between an IL-1 ligand and IL-1R1. This binding event is the first committed step in IL-1 signal transduction and is therefore a focal point for understanding inflammatory disease mechanisms. The interaction is not merely a passive docking event. Structural studies have resolved how IL-1β engages IL-1R1 to form a productive complex that recruits the accessory protein IL-1RAcP and initiates downstream signaling. Natural regulators, including the secreted antagonist IL-1Ra and the decoy receptor IL-1R2, compete for the same binding interface, establishing a tightly controlled system. Because of this central role, GO:0005150 is relevant to immunology, inflammation biology, and drug discovery. For researchers, GO:0005150 provides a precise annotation target when studying ligand-receptor specificity, receptor antagonism, and cytokine-driven pathology. Experimental systems ranging from recombinant peptide screening to CRISPR-engineered cell models have been used to dissect this binding function. This article summarizes the authoritative definition, the genes and proteins involved, disease links, and the research methods used to study interleukin-1, type I receptor binding.
interleukin-1, type I receptor binding At A Glance
| GO ID | GO:0005150 |
|---|---|
| GO term | interleukin-1, type I receptor binding |
| Ontology | molecular_function |
| Synonym | IL-1 type I; interleukin-1, type I receptor ligand |
| Definition | Binding to a Type I interleukin-1 receptor. |
| Major function | Mediates the initial high-affinity interaction between IL-1 ligands and IL-1R1, initiating pro-inflammatory signaling. |
| Primary ligands | IL-1β and IL-1α. |
| Primary receptor | IL-1R1 (Type I interleukin-1 receptor). |
| Key structural evidence | Crystal structure of the IL-1R1–IL-1β complex. |
| Endogenous modulators | IL-1Ra (antagonist) and IL-1R2 (decoy receptor). |
What Is GO:0005150?
GO:0005150 is defined by QuickGO as binding to a Type I interleukin-1 receptor. In practical terms, it is the molecular function of a ligand (typically IL-1α or IL-1β) that physically and selectively associates with IL-1R1. The term is a molecular_function annotation and is distinct from downstream signaling events; it describes the binding interaction itself rather than the cellular response it triggers.
Why Is interleukin-1, type I receptor binding Important in Cell Biology?
GO:0005150 is important because the binding of IL-1 to IL-1R1 is the initiating event of a major pro-inflammatory signaling axis that influences host defense, tissue homeostasis, and disease pathogenesis. Understanding this molecular function helps explain how cytokines achieve receptor specificity and how natural antagonists or decoy receptors dampen signaling. It also provides a mechanistic basis for therapeutic strategies that target the IL-1/IL-1R1 interaction in inflammatory and cardiovascular diseases.
• Defines the first step in IL-1 signal transduction, a central pathway in innate immunity.
• Explains ligand specificity for IL-1R1 versus other cytokine receptors.
• Provides a structural template for designing receptor antagonists.
• Links cytokine binding to atherosclerosis and macrophage-driven inflammation.
• Relevant to kidney disease through IL-1 receptor family signaling.
• Enables comparative immunology studies, including avian IL-1 systems.
• Supports development of soluble receptor therapeutics that block IL-1 activity.
• Guides CRISPR-based functional validation of ligand-receptor interactions.
Molecular Mechanism of interleukin-1, type I receptor binding
Ligand recognition and initial contact
In simple terms: The IL-1 ligand first finds and touches the receptor.
IL-1β and IL-1α are the principal ligands that recognize IL-1R1. The binding event is selective and high affinity, ensuring that the receptor responds specifically to IL-1 family cytokines rather than unrelated ligands. This initial recognition step is the molecular function captured by GO:0005150.
Structural basis of the IL-1R1–IL-1β complex
In simple terms: The 3D shape of the ligand and receptor fit together like a lock and key.
The crystal structure of the Type I interleukin-1 receptor complexed with IL-1β revealed the molecular details of the binding interface. This structure showed how the ligand engages the receptor ectodomain and provided a framework for understanding affinity and specificity. Such structural information is essential for interpreting mutations that alter binding.
Competition by natural antagonists and decoy receptors
In simple terms: Other molecules can block the ligand from binding the receptor.
The IL-1 receptor antagonist (IL-1Ra) and the decoy receptor IL-1R2 compete with IL-1 for the same or overlapping binding sites, thereby modulating the effective concentration of ligand available to IL-1R1. High-affinity type I interleukin-1 receptor antagonists have been discovered through screening of recombinant peptide libraries, demonstrating that the binding interface is druggable. IL-1R2 acts as a decoy and has been implicated in kidney disease biology.
Species variation and soluble receptor blockade
In simple terms: The same binding principle applies across species, and soluble receptors can soak up the ligand.
Soluble type-I interleukin-1 receptor can block chicken IL-1 activity, indicating that the binding function is conserved enough to be studied in non-mammalian models. This cross-species relevance supports the use of diverse experimental systems to probe GO:0005150. It also highlights how soluble receptor constructs can be used as tools to inhibit ligand-receptor binding.
Downstream consequences of binding
In simple terms: Once the ligand binds, it switches on inflammatory signals.
Binding of IL-1 to IL-1R1 is the prerequisite for recruitment of the accessory protein IL-1RAcP and activation of downstream signaling cascades. This connection to signaling explains why GO:0005150 is functionally significant beyond the binding event itself. In macrophages, IL-1/Toll-like receptor signaling can potentiate olfactory receptor 2-driven atherosclerosis, illustrating how this binding function contributes to disease processes.
Key Genes Involved in GO:0005150 interleukin-1, type I receptor binding
The following genes and proteins are directly or functionally associated with interleukin-1, type I receptor binding (GO:0005150) and its regulation.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IL1B | Encodes IL-1β, a principal ligand that binds IL-1R1 | Central to studies of IL-1/IL-1R1 binding and inflammation |
| IL1A | Encodes IL-1α, another ligand for IL-1R1 | Used to compare ligand-specific binding and signaling |
| IL1R1 | Encodes the Type I interleukin-1 receptor, the binding partner in GO:0005150 | Primary target for receptor-binding assays and structural studies |
| IL1RN | Encodes IL-1Ra, a natural antagonist that competes for IL-1R1 binding | Model for antagonist discovery and binding competition |
| IL1R2 | Encodes the decoy receptor IL-1R2 | Studied in kidney disease and as a modulator of ligand availability |
| IL1RAP | Encodes the accessory protein required for signaling after ligand binding | Relevant to downstream consequences of GO:0005150 |
| MYD88 | Adaptor protein in IL-1/Toll-like receptor signaling | Links binding to inflammatory gene expression |
| OR2 | Olfactory receptor 2, implicated in macrophage-driven atherosclerosis | Example of crosstalk with IL-1/TLR signaling |
| NFKB1 | Transcription factor activated downstream of IL-1R1 | Readout of pathway activation after binding |
| TNF | Pro-inflammatory cytokine often co-regulated with IL-1 | Context for inflammatory disease models |
| CXCL8 | Interleukin-8, a chemokine induced by inflammatory signaling | Marker of downstream inflammatory responses |
| IL6 | Cytokine induced by IL-1 signaling | Used as a functional readout in binding studies |
| CASP1 | Inflammasome caspase that processes IL-1β | Upstream of ligand availability for IL-1R1 binding |
| NLRP3 | Inflammasome sensor controlling IL-1β maturation | Relevant to ligand production and binding studies |
| IL1RL1 | IL-1 receptor-like 1, related family member | Comparative studies of IL-1 receptor family binding |
| IL18 | IL-1 family cytokine with distinct receptor | Contrast for specificity of GO:0005150 |
| IL33 | IL-1 family cytokine | Used to distinguish IL-1R1-specific binding |
| TOLLIP | Regulatory protein in IL-1/TLR signaling | Modulates pathway activity after receptor binding |
How Is interleukin-1, type I receptor binding Regulated?
The availability of ligand for IL-1R1 binding is regulated at multiple levels. Inflammasome-dependent processing of pro-IL-1β by caspase-1 controls the amount of mature ligand that can engage the receptor. Natural antagonists such as IL-1Ra and decoy receptors such as IL-1R2 compete for binding and dampen signaling. Soluble forms of the Type I receptor can sequester ligand and block activity, as shown in avian systems. Downstream signaling through MYD88 and NF-κB provides feedback that shapes the inflammatory context in which binding occurs.
interleukin-1, type I receptor binding and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| IL1B | Atherosclerosis and inflammatory disease | IL1B knockout or knock-in cell models |
| IL1R1 | IL-1-driven inflammation | IL1R1 knockout and tagged knock-in for binding assays |
| IL1RN | Inflammatory imbalance due to antagonist deficiency | IL1RN overexpression or point-mutation models |
| IL1R2 | Kidney disease | IL1R2 knockout and overexpression in renal cell models |
| OR2 | Macrophage-driven atherosclerosis | OR2 knockout macrophages with IL-1/TLR stimulation |
Atherosclerosis and cardiovascular inflammation
IL-1/Toll-like receptor signaling potentiates macrophage olfactory receptor 2-driven atherosclerosis, linking the IL-1/IL-1R1 binding axis to plaque formation and cardiovascular disease. This suggests that GO:0005150-dependent events contribute to the inflammatory component of atherosclerosis. Experimental models that manipulate IL-1R1 binding can help define causal contributions.
Kidney disease
Interleukin 1 receptor 2 (IL-1R2) has been studied for its role in kidney disease, where it acts as a decoy receptor that modulates IL-1 availability. Because IL-1R2 competes with IL-1R1 for ligand, its expression levels can influence the extent of GO:0005150-mediated signaling. This makes the IL-1/IL-1R1/IL-1R2 balance relevant to renal pathology.
Inflammatory and innate immune disorders
The IL-1 pathway is a central mediator of innate immunity, and dysregulated binding to IL-1R1 is associated with excessive inflammation. Antagonists such as IL-1Ra and peptide-based type I receptor antagonists have been developed to interfere with this binding event. These strategies underscore the therapeutic relevance of GO:0005150.
From interleukin-1, type I receptor binding-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of IL1R1 abolish IL-1 binding and signaling? | IL1R1 knockout cell line |
| Which residues mediate high-affinity ligand binding? | Point-mutation knock-in of IL1R1 or IL1B |
| Can a tagged receptor be used for binding assays? | Tagged knock-in of IL1R1 |
| Does overexpression of IL-1Ra block binding? | IL1RN overexpression model |
| How does IL-1R2 decoy activity affect kidney cells? | IL1R2 knockout or overexpression |
| Does IL-1/TLR crosstalk require OR2? | OR2 knockout macrophages |
How to Study the interleukin-1, type I receptor binding Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Receptor-binding assay | Affinity and specificity of IL-1 for IL-1R1 | Screening antagonists and ligand variants |
| X-ray crystallography | Atomic structure of the receptor-ligand complex | Mapping binding interface residues |
| CRISPR knockout | Loss-of-function effects on binding and signaling | Testing IL1R1 or IL1B requirement |
| CRISPR knock-in | Effects of specific mutations or tags | Dissecting binding residues |
| Overexpression | Gain-of-function effects of ligands or antagonists | Testing IL1RN or IL1R2 modulation |
| Soluble receptor blockade | Inhibition of ligand activity | Cross-species functional validation |
| Signaling readouts | Downstream NF-κB or cytokine induction | Linking binding to inflammatory output |
| Macrophage atherosclerosis models | IL-1/TLR crosstalk in plaque biology | Studying OR2-dependent inflammation |
Receptor-binding assays
Direct binding assays using recombinant IL-1 ligands and IL-1R1 ectodomains are used to measure affinity and specificity, as demonstrated by peptide library screening for type I receptor antagonists. These assays can be coupled to structural studies to map the binding interface.
Structural biology
X-ray crystallography of the IL-1R1–IL-1β complex provided atomic-level detail of the binding interaction. Such structural data guide mutational analysis and rational design of antagonists.
CRISPR-based functional genomics
CRISPR knockout, knock-in, and overexpression models allow causal testing of genes such as IL1R1, IL1B, and IL1RN in the binding pathway. These models can be combined with signaling readouts to connect binding to downstream effects.
Cross-species and soluble receptor assays
Soluble type-I interleukin-1 receptor has been used to block chicken IL-1 activity, demonstrating a functional assay for ligand-receptor binding across species. This approach is useful when evaluating conservation of GO:0005150.
How CRISPR Can Be Used to Study GO:0005150 interleukin-1, type I receptor binding
Knockout
CRISPR knockout of IL1R1 or IL1B can abolish or reduce interleukin-1, type I receptor binding and its downstream signaling, providing a clean loss-of-function test. Such models are useful for confirming that a candidate gene is required for the binding function.
Point Mutation
Point mutations introduced into IL1R1 or IL1B can be used to test which residues are critical for high-affinity binding, guided by the crystal structure of the complex. This approach allows precise structure-function dissection without deleting the entire gene.
Knock-in
Tagged knock-in of IL1R1 enables detection and purification of the receptor for binding assays while preserving endogenous regulation. Knock-in of disease-associated variants can also model altered binding affinity.
Overexpression
Overexpression of IL1RN or IL1R2 can be used to test whether increased antagonist or decoy receptor levels block IL-1 binding to IL-1R1. This is particularly relevant for kidney disease models involving IL-1R2.
How EDITGENE Supports interleukin-1, type I receptor binding Research
Researchers studying interleukin-1, type I receptor binding-related genes often need to determine whether a candidate gene is causally involved in the binding event or its downstream consequences. EDITGENE provides CRISPR-based cell model services that enable such causal experiments with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for interleukin-1, type I receptor binding research.
Frequently Asked Questions About interleukin-1, type I receptor binding
What is GO:0005150?
GO:0005150 is the Gene Ontology molecular function term for interleukin-1, type I receptor binding, defined as binding to a Type I interleukin-1 receptor.
What genes are involved in interleukin-1, type I receptor binding?
Key genes include IL1B, IL1A, IL1R1, IL1RN, IL1R2, and IL1RAP, which encode the ligands, receptor, antagonist, and accessory proteins.
Which ligands bind the Type I interleukin-1 receptor?
IL-1β and IL-1α are the principal ligands that bind IL-1R1 with high affinity.
What is the structure of the IL-1R1–IL-1β complex?
The crystal structure of the Type I interleukin-1 receptor complexed with IL-1β revealed the atomic details of the binding interface.
How is interleukin-1, type I receptor binding regulated?
It is regulated by ligand processing, natural antagonists such as IL-1Ra, decoy receptors such as IL-1R2, and soluble receptor forms.
What diseases are linked to IL-1 receptor binding?
Atherosclerosis, kidney disease, and inflammatory disorders have been linked to IL-1/IL-1R1 signaling.
How can CRISPR be used to study GO:0005150?
CRISPR knockout, knock-in, point mutation, and overexpression models can test the requirement and specificity of genes involved in IL-1 binding.
What methods measure interleukin-1 receptor binding?
Receptor-binding assays, X-ray crystallography, and soluble receptor blockade assays are commonly used.
Is IL-1R2 a decoy receptor?
Yes, IL-1R2 acts as a decoy receptor that modulates IL-1 availability and has been studied in kidney disease.
Can soluble IL-1 receptor block binding?
Yes, soluble type-I interleukin-1 receptor has been shown to block chicken IL-1 activity.
Conclusion
GO:0005150, interleukin-1, type I receptor binding, defines the critical molecular interaction between IL-1 ligands and IL-1R1 that initiates a major pro-inflammatory signaling axis. Structural, biochemical, and genetic studies have clarified the binding interface and its regulation by antagonists and decoy receptors. This function is directly relevant to atherosclerosis, kidney disease, and other inflammatory conditions. CRISPR-based cell models provide powerful tools to test causality and to develop therapeutic strategies targeting this binding event.
References
- 1. Weber A et al.. 2010. Interleukin-1 (IL-1) pathway.. Sci Signal 3(105):cm1 PMID: 20086235
- 2. Matsushima K et al.. 2022. Interleukin-8: An evolving chemokine.. Cytokine 153:155828 PMID: 35247648
- 3. Stylianou E et al.. 1998. Interleukin-1.. Int J Biochem Cell Biol 30(10):1075-9 PMID: 9785472
- 4. Zhang L et al.. 2025. Interleukin-1/Toll-like receptor signaling potentiates macrophage olfactory receptor 2-driven atherosclerosis.. Cell Rep 44(12):116639 PMID: 41343277
- 5. Yanofsky SD et al.. 1996. High affinity type I interleukin 1 receptor antagonists discovered by screening recombinant peptide libraries.. Proc Natl Acad Sci U S A 93(14):7381-6 PMID: 8693002
- 6. Hu H et al.. 2024. Role of Interleukin 1 Receptor 2 in Kidney Disease.. J Interferon Cytokine Res 44(4):170-177 PMID: 38527174
- 7. Vigers GP et al.. 1997. Crystal structure of the type-I interleukin-1 receptor complexed with interleukin-1beta.. Nature 386(6621):190-4 PMID: 9062193
- 8. Klasing KC et al.. 2001. Soluble type-I interleukin-1 receptor blocks chicken IL-1 activity.. Dev Comp Immunol 25(4):345-52 PMID: 11246074
